MYELOMA CANADA NEWS
December 2016
pCODR EXPERT REVIEW COMMITTEE DOES NOT RECOMMEND REIMBURSEMENT FOR
DARATUMUMAB (DARZALEX)
 
On December 1, 2016, the pan-Canadian Oncology Drug Review (pCODR) Expert Review committee, made a final recommendation against the reimbursement of daratumumab (Darzalex) for the treatment of patients with myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD); or have failed or are intolarent to a PI and who have failed or are intolarent to an IMid.
 
The committee made this recommendation because it was unable to conclude that, based on the available evidence, there is a net clinical benefit of daratumumab compared with other treatments.

Fore more information please visit the CADTH website HERE

Although we are disappointed with the decision taken by pCODR, Myeloma Canada will continue to work with the drug manufacturers to ensure treatment options are available to Canadian patients.

MYELOMA CANADA IS PLEASED TO ANNOUNCE REVLIMID® AS FIRST-LINE TREATMENT FOR NON-TRANSPLANT ELIGIBLE MYELOMA PATIENTS NOW FUNDED IN NOVA SCOTIA AND THE YUKON
DONATE SECURITIES BEFORE THE END OF THE TAX YEAR
 
Supporting charitable organizations is a valued and respected part of the Canadian society. To encourage the gift of shares, the government has simplified the process by removing capital gains tax on shares and stocks donated. You can donate your shares to Myeloma Canada in a simple electronic transfer. Once received, we immediately issue a tax receipt for the fair market value. If deductions cannot be used for that calendar year, you can carry the remainder over the next five years.

DID YOU KNOW?

If shares have appreciated in value at the time of transfer to Myeloma Canada, you pay no tax on the gain in value and still receive a charitable tax receipt for the highest value of the shares.

 
GIVING IN SHARES TO MYELOMA CANADA HAS ITS BENEFITS 


MYELOMA CANADA EDUCATIONAL WEBINARS: COMING SOON IN JANUARY 2017


Stay tuned for the launch of Myeloma Canada's educational webinar series starting in January 2017. All you need is a computer or tablet and an internet connection and you're ready to go!


The first two webinars presented by Dre Julie Côté (French) and Dr Arleigh McCurdy  (English) will feature highlights from the 2016 American Society of Hematology (ASH) conference.

Details to be announced early January.

Please note during the holidays Myeloma Canada's hours of operation will be limited between December 23rd, 2016, to January 9th, 2017. During this time, you may contact us anytime by email at contact@myeloma.ca. A member from our team will contact you within 48 hours.

Happy holidays and best wishes to you and yours for 2017!

See what's happening on the social sites of Myeloma Canada:

  Facebook    Twitter    LinkedIn    View our videos on YouTube   View our photos on flickr   View on Instagram